SCHEMBL711999

SCHEMBL711999

CC(C)N(C)S(=O)(=O)NC(=O)c1ccc(F)c(NC(=O)Oc2ccccc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.46
HDAC8 Q9BY41 2/20 0.46
HDAC6 Q9UBN7 2/20 0.46
ALDH1A1 P00352 4/20 0.45
KDM4E B2RXH2 2/20 0.45
GAA P10253 2/20 0.45
HPGD P15428 2/20 0.45
GLA P06280 1/20 0.45
ATM Q13315 1/20 0.45
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
SCN9A Q15858 1/20 0.41
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
MAPT P10636 2/20 0.39
THRB P10828 2/20 0.39
GFER P55789 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL711773 0.87 HDAC6 (0.42) HDAC1HDAC8HDAC6ALDH1A1SCN9A
SCHEMBL711275 0.85 HDAC6 (0.41) HDAC1HDAC8HDAC6ALDH1A1HPGD
SCHEMBL710134 0.84 ALDH1A1 (0.47) HDAC1HDAC8HDAC6ALDH1A1KDM4E
SCHEMBL712003 0.80 HPGD (0.47) ALDH1A1KDM4EHPGDRAB9ANPC1
SCHEMBL12011295 0.76 HDAC6 (0.39) HDAC1HDAC8HDAC6ALDH1A1GLA
SCHEMBL29739688 0.74 NPC1 (0.56) ALDH1A1KDM4EGAAHPGDGLA
SCHEMBL29739318 0.74 ALDH1A1 (0.64) ALDH1A1KDM4EGAAHPGDGLA
SCHEMBL714409 0.74 HDAC6 (0.43) HDAC1HDAC8HDAC6KDM4ESCN9A
SCHEMBL16303664 0.73 RAB9A (0.61) ALDH1A1KDM4EGAAHPGDGLA
SCHEMBL27881580 0.72 HDAC1 (0.47) HDAC1HDAC8HDAC6ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8252925-B2 Method for the production of 3-phenyl(thio)uracils and dithiouracils BASF AKTIENGESELLSCHAFT (DE) 2012-08-28 US disclosed
US-8252925-B2 Method for the production of 3-phenyl(thio)uracils and dithiouracils BASF AKTIENGESELLSCHAFT (DE) 2012-08-28 US disclosed
US-8124818-B2 Method for the production of 3-phenyl(thio) uracils and dithiouracils BASF AKTIENGESELLSCHAFT (DE) 2012-02-28 US disclosed
US-8124818-B2 Method for the production of 3-phenyl(thio) uracils and dithiouracils BASF AKTIENGESELLSCHAFT (DE) 2012-02-28 US disclosed
US-20110152522-A1 METHOD FOR THE PRODUCTION OF 3-PHENYL(THIO) URACILS AND DITHIOURACILS BASF AKTIENGESSELSCHAFT (DE) 2011-06-23 US disclosed
US-20110152522-A1 METHOD FOR THE PRODUCTION OF 3-PHENYL(THIO) URACILS AND DITHIOURACILS BASF AKTIENGESSELSCHAFT (DE) 2011-06-23 US disclosed
US-20080033174-A1 Method for the Production of 3-Phenyl (Thio) Uracils and Dithiouracils BASF AKTIENGESELLSCHAFT (DE) 2008-02-07 US disclosed
US-20080033174-A1 Method for the Production of 3-Phenyl (Thio) Uracils and Dithiouracils BASF AKTIENGESELLSCHAFT (DE) 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033174-A1 Method for the Production of 3-Phenyl (Thio) Uracils and Dithiouracils TPMT, TYMP, TYMS HDAC1 2627/4885HDAC8 4101/4885HDAC6 2437/4885
US-20110152522-A1 METHOD FOR THE PRODUCTION OF 3-PHENYL(THIO) URACILS AND DITHIOURACILS TPMT, TYMP, TYMS HDAC1 2627/4885HDAC8 4101/4885HDAC6 2437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.